# OnCo record nsabp-b51 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nsabp-b51/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nsabp-b51", "NCT01872975" ;
  schema:name "NSABP B-51 / RTOG 1304"@en ;
  schema:alternateName "NSABP B-51"@en, "RTOG 1304"@en, "NRG Oncology/NSABP B-51"@en ;
  schema:description "If chemotherapy given before surgery clears the lymph nodes completely, irradiating those nodes afterwards adds nothing. Fewer than one woman in ten had the cancer come back either way, and the difference between the two groups was within chance."@en ;
  schema:url <https://onco.cc/trials/nsabp-b51/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT01872975>, <https://doi.org/10.1056/NEJMoa2414859> ;
  onco:status "negative" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/breast-cancer/>, <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/breast-her2-positive/>, <https://onco.cc/cancers/tnbc/> ;
  onco:technologies <https://onco.cc/technologies/imrt-igrt/> ;
  onco:companies <https://onco.cc/companies/nrg-oncology/>, <https://onco.cc/companies/nsabp-foundation/> ;
  onco:terms <https://onco.cc/terms/neoadjuvant-versus-adjuvant-breast/>, <https://onco.cc/terms/targeted-axillary-dissection/>, <https://onco.cc/terms/post-mastectomy-radiotherapy/>, <https://onco.cc/terms/pcr/> ;
  onco:trials <https://onco.cc/trials/atnec/>, <https://onco.cc/trials/acosog-z1071/>, <https://onco.cc/trials/supremo/>, <https://onco.cc/trials/ma-20/> .